Relay Therapeutics (RLAY) Research & Development (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Research & Development data on file, last reported at $70.6 million in Q1 2026.

• Research & Development for Q1 2026 came in at $70.6 million, down 4.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $258.1 million (down 16.86% YoY), and the FY2025 annual result was $261.4 million, down 18.08% from the prior year.
• Research & Development climbed to $70.6 million in Q1 2026 per RLAY's latest filing, from $55.4 million in the prior quarter.
• Over five years, Research & Development peaked at $92.0 million in Q2 2024 and troughed at $51.7 million in Q1 2022.
• A 5-year average of $72.2 million and a median of $70.6 million in 2026 frame the typical range for Research & Development.
• The sharpest annual moves came in 2022 and 2025: Research & Development jumped 68.73% in 2022, then sank 30.54% in 2025.
• A 5-year view of Research & Development shows it stood at $67.3 million in 2022, then advanced by 15.19% to $77.5 million in 2023, then slipped by 12.16% to $68.1 million in 2024, then declined by 18.6% to $55.4 million in 2025, then climbed by 27.34% to $70.6 million in 2026.
• Business Quant data shows RLAY's Research & Development at $70.6 million in Q1 2026, $55.4 million in Q4 2025, and $68.3 million in Q3 2025.